[H2020 I RESEARCH FUNDING]
Event details
Date | 28.03.2017 |
Hour | 16:59 › 17:00 |
Category | Call for proposal |
IMI 2 - Call 10
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
Submission deadline: 28 Mars 2017
Subject:
For more information and application : Please have a look at the IMI's website and the online webinar.
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
Submission deadline: 28 Mars 2017
Subject:
- Topic 1: Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
- Topic 2: How big data could support better diagnosis and treatment outcomes for prostate cancer (part of the Big Data for Better Outcomes programme)
- Topic 3: Improving the care of patients suffering from acute or chronic pain (this topic includes three subtopics on patient reported outcomes; biomarkers; and chronic pelvic pain)
- Topic 4: Creation of a pan-European paediatric clinical trials network
- Topic 5: Biomanufacturing 2020: development of innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
- Topic 6: Unlocking the solute carrier gene-family for effective new therapies (unlock SLCs)
- Topic 7: Patient perspectives in medicines lifecycle
- Topic 8: Personalised medicine approaches in autism spectrum disorders
For more information and application : Please have a look at the IMI's website and the online webinar.
Practical information
- General public
- Free